iBio (NASDAQ:IBIO) Downgraded by Wall Street Zen to “Sell”

iBio (NASDAQ:IBIO – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Several other analysts have also recently commented on the stock. HC Wainwright initiated coverage on shares of iBio in a research note on Thursday, September 17th. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a research note on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.00.

Check Out Our Latest Analysis on IBIO

iBio Price Performance

IBIO stock opened at $0.82 on Friday. The company has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.59. iBio has a 12 month low of $0.68 and a 12 month high of $3.82. The company has a market cap of $57.78 million, a price-to-earnings ratio of -2.93 and a beta of 1.47.

iBio (NASDAQ:IBIO – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $0.03 million. As a group, analysts anticipate that iBio will post -0.36 earnings per share for the current year.

Institutional Trading of iBio

A number of institutional investors have recently added to or reduced their stakes in the stock. Readystate Asset Management LP acquired a new position in iBio during the third quarter worth about $26,000. R Squared Ltd purchased a new position in iBio in the third quarter valued at about $29,000. Headlands Technologies LLC lifted its position in shares of iBio by 333.0% during the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after acquiring an additional 36,463 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of iBio during the 3rd quarter valued at approximately $105,000. Finally, Bank of America Corp DE boosted its stake in shares of iBio by 150.8% during the 1st quarter. Bank of America Corp DE now owns 290,413 shares of the company’s stock worth $552,000 after acquiring an additional 174,620 shares in the last quarter. Hedge funds and other institutional investors own 7.90% of the company’s stock.

iBio Company Profile

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Featured Stories

Analyst Recommendations for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.